917392-54-2

Basic information

• Product Name: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester
• Synonyms: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester;4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)-benzoic acid Methyl ester;Methyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate, Methyl 4-Methyl-3-(4-(pyridin-3-yl)pyriMidin-2-ylaMino)benzoate;Methyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate;Benzoicacid, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]-, Methyl ester
• CAS NO: 917392-54-2
• Molecular Formula: C₁₈H₁₆N₄O₂
• Molecular Weight: 320.35
• Mol File: 917392-54-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 538.59°C at 760 mmHg
• Flash Point: 279.53°C
• Appearance: /
• Density: 1.258
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.634
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 2.70±0.12(Predicted)
• CAS DataBase Reference: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester(917392-54-2)
• EPA Substance Registry System: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester(917392-54-2)

Safety Data

• Hazardous Substances Data: 917392-54-2(Hazardous Substances Data)

Usage

Uses

Methyl 4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate is an intermediate used in the synthesis of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide (M326838), which is an impurity of Nilotinib (N465300), a possible agent in the treatment of chronic myelogenous leukemia.

InChI:InChI=1/C18H16N4O2/c1-12-5-6-13(17(23)24-2)10-16(12)22-18-20-9-7-15(21-18)14-4-3-8-19-11-14/h3-11H,1-2H3,(H,20,21,22)

Upstream product

• 1025716-99-7 3-[(aminoiminomethyl)amino]-4-methylbenzoic acid methylester mononitrate 
• 55314-16-4 (E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 90347-66-3 methyl 3-iodo-4-methylbenzoate 
• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 1692-25-7 3-pyridylboronic acid 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 483324-01-2 2-chloro-4-(pyridin-3-yl)pyrimidine 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 67-56-1 methanol 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 350-03-8 methyl-3-pyridylketone 
• 1025716-98-6 3-guanidino-4-methylbenzoic acid methyl ester 

Downstream Products

• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 641571-10-0 nilotinib 
• 1205540-16-4 N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide 
• 1186619-20-4 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid N'-4-[[(4-methyl-1-piperazinyl)methyl]benzoyl]hydrazide 
• 1186619-25-9 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid N'-[3,5-bis(trifluoromethyl)benzoyl]hydrazide 
• 1186620-26-7 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid N'-(3-trifluoromethyl-4-methylbenzoyl)hydrazide 
• 1186619-38-4 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid N'-(pyridin-3-carbonyl)hydrazide 
• 1079911-30-0 {5-[5-(3-difluoromethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-2-methyl-phenyl}-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 
• 1079904-27-0 [2-methyl-5-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 

Relevant articles and documents

SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE

Processes and useful intermediates for the synthesis of the tyrosine kinase inhibitors Formula (II) nilotinib and Formula (IV) imatinib. Key intermediates, method for their synthesis and their use in a divergent synthesis, making use of a Curtius rearrangement, to nilotinib and imatinib are described.

DEUTERATED AMINOPYRIDINE COMPOUNDS

The present disclosure is directed to Compound I and Compound II as well as pharmaceutical compositions including Compound I or Compound II, or mixtures thereof. The disclosure is additionally directed to methods of making the aforementioned compounds and

Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: Application to the synthesis of nilotinib

The completely N1-selective Pd-catalyzed arylation of unsymmetric imidazoles with aryl halides and triflates is described. This study showed that imidazoles have a strong inhibitory effect on the in situ formation of the catalytically active Pd(0)-ligand complex. The efficacy of the N-arylation reaction was improved drastically by the use of a preactivated solution of Pd2(dba)3 and L1. From these findings, it is clear that while imidazoles can prevent binding of L1 to Pd, once the ligand is bound to the metal, these heterocycles do not displace it. The utility of the present catalytic system was demonstrated by the regioselective synthesis of the clinically important tyrosine kinase inhibitor nilotinib.